Cargando…
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/ https://www.ncbi.nlm.nih.gov/pubmed/27403342 http://dx.doi.org/10.1155/2016/3852126 |
_version_ | 1782440012673974272 |
---|---|
author | Bell, Allison M. Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. |
author_facet | Bell, Allison M. Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. |
author_sort | Bell, Allison M. |
collection | PubMed |
description | Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C. |
format | Online Article Text |
id | pubmed-4925941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49259412016-07-11 Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C Bell, Allison M. Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. Int J Hepatol Review Article Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C. Hindawi Publishing Corporation 2016 2016-06-15 /pmc/articles/PMC4925941/ /pubmed/27403342 http://dx.doi.org/10.1155/2016/3852126 Text en Copyright © 2016 Allison M. Bell et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bell, Allison M. Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title_full | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title_fullStr | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title_full_unstemmed | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title_short | Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C |
title_sort | elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis c |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/ https://www.ncbi.nlm.nih.gov/pubmed/27403342 http://dx.doi.org/10.1155/2016/3852126 |
work_keys_str_mv | AT bellallisonm elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc AT wagnerjamiel elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc AT barberkatiee elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc AT stoverkaylar elbasvirgrazoprevirareviewofthelatestagentinthefightagainsthepatitisc |